<DOC>
	<DOCNO>NCT02087475</DOCNO>
	<brief_summary>Colorectal cancer ( CRC ) one leading cause cancer death China . Although multiple treatment modality include surgery , radiotherapy chemotherapy develop , prognosis advance CRC still remain poor . While around 30 % resectable advanced CRC could cure . This study design compare perioperative FOLFIRI versus adjuvant FOLFIRI resectable advance CRC expose oxaliplatin open-label , phase III mode .</brief_summary>
	<brief_title>Perioperative FOLFIRI VS Adjuvant FOLFIRI Resectable Advanced CRC Failed Oxaliplatin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Age:1880 ECOG score : 0 1 Histological confirm Colorectal Adenocarcinoma History exposure oxaliplatin With local recurrent metastatic focus Tumor resectable confirm less 3 hepatobiliary surgeon Informed content acquire History Exposure Irinotecan Received surgery recently 4 week recover surgery Other history cancer recent 5 year Fluorouracil allergy dihydropyrimidine dehydrogenase defect Women potential pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>